HISTONE DEACETYLASE INHIBITOR
Zolinza is a prescription medication approved by the Food and Drug Administration (FDA) to treat skin symptoms in people with cutaneous T-cell lymphoma (CTCL). Zolinza is indicated for use in cases where CTCL has persisted, progressed, or recurred despite two other systemic therapies. Zolinza is also referred to by its drug name, Vorinostat.
Zolinza is an anticancer drug. Zolinza is a member of a class of drugs called histone deacetylase inhibitors. Zolinza is believed to work by killing cancer cells and slowing their growth.
How do I take it?
Zolinza is taken orally once daily.
Zolinza comes in capsule form.
The FDA-approved label for Zolinza lists common side effects including fatigue, changes to the sense of taste, nausea, diarrhea, low blood cell counts, and loss of appetite.
Rare but serious side effects listed for Zolinza include dangerously low blood cell counts, severe gastrointestinal symptoms, fetal harm in pregnant women, and potentially life-threatening blood clots.
For more details about this treatment, visit:
Zolinza highlights of prescribing information (PDF) – Merck
Treatment for Indolent NHL Subtypes – Leukemia & Lymphoma Society
We never share your personal information with anyone.